LOAMU
UTHR icon

Lombard Odier Asset Management (USA)’s United Therapeutics UTHR Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-472
Closed -$280K – 276
2026
Q1 		$280K Buy
+472
New +$235K 0.03% 201
2025
Q4 		– Sell
-717
Closed -$301K – 430
2025
Q3 		$301K Buy
+717
New +$241K 0.02% 361
2015
Q1 		– Sell
-50,000
Closed -$6.47M – 206
2014
Q4 		$6.47M Buy
+50,000
New +$6.44M 0.44% 64

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Lombard Odier Asset Management (USA)'s UTHR Position: Q2 2026 in Review

Lombard Odier Asset Management (USA) sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 472 shares — an estimated $280K sold.

Lombard Odier Asset Management (USA) first reported a position in UTHR in Q4 2014 and held it in 3 quarters. The position peaked at $6.47M in Q4 2014. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Lombard Odier Asset Management (USA) reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 472 United Therapeutics shares in Q2 2026, an estimated $280K.
  • Lombard Odier Asset Management (USA) first reported a position in United Therapeutics in Q4 2014 and held it in 3 quarters.
  • Lombard Odier Asset Management (USA)'s United Therapeutics position peaked at $6.47M in Q4 2014.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q2 2026, filed 14 Aug 2026.